Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management

References

• D'Amato G, Steinert DM, McAuliffe JC, Trent JC. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005;12:44–56.
   PubMedGoogle Scholar
• Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, . Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–80.
   PubMed Web of Science ®Google Scholar
• Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2):ii35–8.
   PubMedGoogle Scholar
• NCCN clinical practice guidelines in oncology: Soft tissue sarcoma. http://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf
   Google Scholar
• Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471–8.
   PubMed Web of Science ®Google Scholar
• Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, . An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91:4070–6.
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, . In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327–37.
   PubMed Web of Science ®Google Scholar
• Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, . SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757–66.
   PubMed Web of Science ®Google Scholar
• O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, . SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597–605.
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. Data on file.
   Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, . Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329–38.
   PubMed Web of Science ®Google Scholar
• Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, . Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007;12:107–13.
   PubMed Web of Science ®Google Scholar
• Blanke CD, Rankin C, Demetri GD, Ryan CW, von MM, Benjamin RS, . Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626–32.
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, . Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004;364:1127–34.
   PubMed Web of Science ®Google Scholar
• Safety and effectiveness of daily dosing with sunitinib or imatinib in patients with gastrointestinal stromal tumors. PrFont34Bin 0BinSub0Frac0Def1Margin0Margin0Jc1Indent1440Lim0 Lim1ClinicalTrials.gov Identifier: NCT00372567. Accessed August 1, 2008 from http://www.clinicaltrials.gov/ct2/show/NCT00372567?term=nct00372567&rank=1.
   Google Scholar
• George S, Blay JY, Casali PG, Le CA, Stephenson P, DePrimo SE, . Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959–68.
   PubMed Web of Science ®Google Scholar
• Reichardt P, Kang Y, Ruka W, Seddon B, Guerriero B, Breazna A, . Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST. J Clin Oncol 2008;26(15S):Abstract 10548.
   Google Scholar
• Imatinib mesylate and sunitinib in treating patients with gastrointestinal stromal tumors. Study NCT00573404. http:// www.clinicaltrials.gov/ct2/show/NCT00596830?term=CP-751%2C871&phase=2&rank=2.
   Google Scholar
• Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, . Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25–35.
   PubMed Web of Science ®Google Scholar
• Morgan JA, Demetri GD, Fletcher JA, George S, Desai J, Maki RG, . Patients with imatinib mesylate-resistant GIST exhibit durable responses to sunitinib malate (SU11248). Oral presentation: European Cancer Conference (ECCO 13), Paris, France, 30 October-3 November 2005. Eur J Cancer Suppl 2005, 3:421 Abstract 1456.
   Google Scholar
• Protocol No. RTKC-0511-013: A phase I/II study of SU011248 in the treatment of patients with malignant gastrointestinal stromal tumor (GIST) who are intolerant of, or with disease progressing on, imatinib mesylate (Gleevec™). November 2007. Accessed September 9, 2008 from http:// www.clinicalstudyresults.org/drugdetails/?company_id=2&inn_name_id=402&indication_id=1044&sort=c.company_ name&page=1&drug_id=2331
   Google Scholar
• Demetri GD, Huang X, Garrett CR, Schöffski P, Blackstein ME, Shah MH, . Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure. J Clin Oncol 2008;26:Abstract 10524.
   Google Scholar
• Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, . Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011–9.
   PubMed Web of Science ®Google Scholar
• Pfizer Inc. SUTENT, summary of product characteristics. August 2008.
   Google Scholar
• Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, . Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26:5204–12.
   PubMed Web of Science ®Google Scholar
• Early detection of cardiotoxicity during sunitinib or sorafenib chemotherapy using cardiac biomarkers. NCT0053206. Accessed October 9, 2008 from http://www.clinicaltrials.gov/ct2/results?term=nct00532064.
   Google Scholar
• Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, . Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660–4.
   PubMed Web of Science ®Google Scholar
• Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, . A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007;92:3531–4.
   PubMed Web of Science ®Google Scholar
• Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, . The clinical implications of sunitinib-induced hypothyroidism: A prospective evaluation. Br J Cancer 2008;99:448–54.
   PubMed Web of Science ®Google Scholar
• Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, . Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007;17:351–5.
   PubMed Web of Science ®Google Scholar
• Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, . Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491–500.
   PubMed Web of Science ®Google Scholar
• Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multi-targeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008;16:557–66.
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008;19:1955–61.
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, . Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008;13:1001–11.
   PubMed Web of Science ®Google Scholar
• Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007;18:1745–7.
   PubMedGoogle Scholar
• Saylor PJ, Reid TR. Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib. J Clin Oncol 2007;25:3544–6.
   PubMed Web of Science ®Google Scholar
• Blanke CD, Demetri GD, von MM, Heinrich MC, Eisenberg B, Fletcher JA, . Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620–5.
   PubMed Web of Science ®Google Scholar
• Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, . Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908–16.
   PubMed Web of Science ®Google Scholar
• Park YH, Park HJ, Kim BS, Ha E, Jung KH, Yoon SH, . BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett 2006;243:16–22.
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Kotasek D, Le CA, Reichard P, Judson IR, . Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analysis of EORTCISG-AGITG study 62005. Eur J Cancer 2007;43:974–8.
   PubMed Web of Science ®Google Scholar
• Perik PJ, Rikhof B, de Jong FA, Verweij J, Gietema JA, van der Graaf WT. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Ann Oncol 2008;19:359–61.
   PubMed Web of Science ®Google Scholar
• de Groot JW, Zonnenberg BA, Plukker JT, van der Graaf WT, Links TP. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 2005;78:433–8.
   PubMed Web of Science ®Google Scholar
• de Groot JW, Links TP, van der Graaf WT. Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine. Ann Oncol 2006;17:1719–20.
   PubMed Web of Science ®Google Scholar
• Dora JM, Leie MA, Netto B, Fogliatto LM, Silla L, Torres F, . Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients. Eur J Endocrinol 2008;158:771–2.
   PubMed Web of Science ®Google Scholar
• Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, . Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006–13.
   PubMed Web of Science ®Google Scholar
• Pariente A, Etcharry F, Cales V, Laborde Y, Ferrari S, Biour M. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. Eur J Gastroenterol Hepatol 2006;18:785–7.
   PubMed Web of Science ®Google Scholar
• Pinder EM, Atwal GSS, Ayantunde A, Khan S, Sokal M, McCulloch T, . Tumour lysis syndrome occurring in a patient with metastatic gastrointestinal stromal tumour treated with Glivec (imatinib mesylate, Gleevec, STI571). Sarcoma 2007;2007:82012.
   PubMedGoogle Scholar
• Veneri D, Franchini M, Bonora E. Imatinib and regression of type 2 diabetes. N Engl J Med 2005;352:1049–50.
   PubMed Web of Science ®Google Scholar
• Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol 2004;22:4653–5.
   PubMed Web of Science ®Google Scholar
• Billemont B, Medioni J, Taillade L, Helley D, Meric JB, Rixe O, . Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 2008;99:1380–2.
   PubMed Web of Science ®Google Scholar
• Templeton A, Brandle M, Cerny T, Gillessen S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol 2008;19:824–5.
   PubMed Web of Science ®Google Scholar
• Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788–95.
   PubMed Web of Science ®Google Scholar
• Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007;7:475–85.
   PubMed Web of Science ®Google Scholar
• Robert C, Faivre S, Raymond E, Armand JP, Escudier B. Subungual splinter hemorrhages: A clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med 2005;143:313–4.
   PubMed Web of Science ®Google Scholar
• Iitaka M, Miura S, Yamanaka K, Kawasaki S, Kitahama S, Kawakami Y, . Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 1998;83:3908–12.
   PubMed Web of Science ®Google Scholar
• Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol 2000;166:475–80.
   PubMed Web of Science ®Google Scholar
• Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D, . Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracilfed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 1997;15:2687–98.
   PubMed Web of Science ®Google Scholar
• Wang JF, Milosveski V, Schramek C, Fong GH, Becks GP, Hill DJ. Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J Endocrinol 1998;157:5–12.
   PubMed Web of Science ®Google Scholar
• Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42:3127–39.
   PubMed Web of Science ®Google Scholar
• Roodhart JM, Langenberg MH, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 2008;3:132–43.
   PubMedGoogle Scholar
• Hasan S, Dinh K, Lombardo F, Dawkins F, Kark J. Hypopigmentation in an African patient treated with imatinib mesylate: A case report. J Natl Med Assoc 2003;95:722–4.
   PubMedGoogle Scholar
• Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 1998;391:298–301.
   PubMed Web of Science ®Google Scholar
• Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003;98:2483–7.
   PubMed Web of Science ®Google Scholar
• O'Sullivan S, Naot D, Callon K, Porteous F, Horne A, Wattie D, . Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 2007;22:1679–89.
   PubMed Web of Science ®Google Scholar
• Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008;118:84–95.
   PubMed Web of Science ®Google Scholar
• Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332–44.
   PubMed Web of Science ®Google Scholar
• Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, . Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917–30.
   PubMed Web of Science ®Google Scholar
• Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies. Oncologist 2008;13:1084–96.
   PubMed Web of Science ®Google Scholar
• Negrier S, Ravaud A. Optimisation of sunitinib therapy in metastatic renal cell carcinoma: Adverse-event management. Eur J Cancer Suppl 2007;5:12–9.
   Web of Science ®Google Scholar
• Roigas J. Clinical management of patients receiving tyrosine kinase inhibitors for advanced renal cell carcinoma. Eur Urol Suppl 2008;7:593–600.
   Google Scholar
• Raut CP, Morgan JA, Quigley MT, George S, Wagner AJ, Demetri DG, . Perioperative sunitinib dosing around extensive resections of imatinib-resistant metastatic gastrointestinal stromal tumors. J Clin Oncol. 2007;25 ASCO Annual Meeting Proceedings Part I (18S):Abstract 10044.
   PubMedGoogle Scholar
• Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, . Treatment interruptions and non-adherence with imatinib and associated healthcare costs: A retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007;25:481–96.
   PubMed Web of Science ®Google Scholar
• Tuma RS. Disease progression in some cancers may be due to low blood levels of targeted therapies. J Natl Cancer Inst 2008;100:912–3.
   PubMedGoogle Scholar
• A population pharmacokinetic/pharmacodynamic (PK/PD) meta-analysis of sunitinib in patients with gastrointestinal stromal tumour. Presented at the 19th International Congress on Anti-Cancer Treatment, Paris, France.
   Google Scholar
• Wolter P, Beuselinck B, Pans S, Schoffski P. Flare-up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Acta Oncol 2008;48:621–4.
   Google Scholar
• Houk B, Bello CL, Michaelson MD, Bukowski RM, Redman B, Hudes GR, . A population pharmacokinetic/pharmacodynamic (PK/PD) analysis of exposure-response for sunitinib in metastatic renal cell carcinoma (mRCC). Eur J Cancer Suppl 2007;5 (299 Abstract 4.505).
   Google Scholar